GSK 299423
Names | |
---|---|
Preferred IUPAC name 6-Methoxy-4-[2-(4-{[(2H-[1,3]oxathiolo[5,4-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)ethyl]quinoline-3-carbonitrile | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChemSpider |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | C25H27N5O2S |
Molar mass | 461.58 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references |
Chemical compound
GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.[1][2][3]
No animal studies have been reported. No application has been made for human clinical trials.[citation needed]
References
- ^ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria[permanent dead link]," The Wall Street Journal, August 4, 2010
- ^ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' Archived 2010-08-16 at the Wayback Machine" Daily Finance, August 6, 2010
- ^ Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. 466 (7309): 935–40. Bibcode:2010Natur.466..935B. doi:10.1038/nature09197. PMID 20686482. S2CID 205221405. (primary source)
- v
- t
- e
microbiology
and ecology
Oxygen preference | |
---|---|
Other |
Cell envelope | |
---|---|
Outside envelope | |
Composite |
and evolution
- Bacteria (classifications)
- Bacterial phyla
- Former groupings: Schizomycetes
- Monera
- Prokaryota
- Category
- Commons
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e